Foundational Control of Sustained High Blood Pressure

Vasalat is primarily indicated for the long-term management of high systemic blood pressure (hypertension), a condition marked by elevated blood pressure that creates noticeable physiological strain on the cardiovascular system. The core therapeutic benefit is to lower blood pressure, which plays a role in managing the overall risk of serious cardiovascular complications. The medication is commonly used to address conditions presenting with systemic discomfort and is relevant for patients needing sustained support.

“It provides support that assists with maintaining functional stability in conditions characterized by periods of heightened symptoms.”

Indications commonly addressed by Vasalat include hypertension, chronic stable angina, and vasospastic angina.

---

Relief and Supportive Management for Angina and CAD

The medication is also commonly used to manage the symptom clusters of chest discomfort associated with chronic stable angina and the intense, episodic spasms of vasospastic angina (Prinzmetal's). It is relevant for easing symptoms that interfere with daily comfort. For patients with recently documented Coronary Artery Disease (CAD), it contributes to improved comfort during symptomatic periods and may be part of a strategy to support management of risk factors related to serious procedures and hospitalization for angina.

Quick Fact: Relief for Chest Discomfort
This medication is applied in scenarios where additional management of angina (chest pain) is required, supporting the patient by easing the overall symptom load related to arterial stiffness and spasms.

Regulatory References

1. DailyMed/NLM Drug Label

Vasalat's eligibility is strictly defined by regulatory guidelines, focusing on absolute contraindications and population-specific restrictions.

Eligibility Scope

Category	Regulatory Status
Populations Allowed	Adults for hypertension and angina. Pediatric patients 6 years and older for hypertension only.
Populations Contraindicated	Patients with known hypersensitivity to Amlodipine, other dihydropyridine derivatives, or any component. May also be contraindicated in severe hypotension and shock (including cardiogenic shock).
Pediatric Restriction	Use is not established or not recommended for children younger than 6 years of age.
Conditional Use	Caution is mandatory in patients with severe heart failure (NYHA Class III and IV) and severe aortic stenosis. Therapy requires the lowest initial dose and slow titration for patients with severe hepatic impairment.
Reproductive Status	Use during pregnancy is conditional (permitted only if benefit justifies risk). Breastfeeding is generally not recommended or requires discontinuation of the medicine due to excretion into human milk.

Connection to the overall eligibility profile

Official documents prohibit use based on immune history or acute cardiovascular instability. Eligibility is further constrained by specific age minimums and data limitations. Conditional use applies to populations with compromised liver function or certain severe cardiovascular conditions, defining the specific regulatory constraints under which the medicine may be used.

Interactions with other medicines and products

The interaction profile of Vasalat (Amlodipine) is defined by its hepatic metabolism and the potential for additive pharmacodynamic effects, as documented in official regulatory sources. The primary pharmacokinetic interactions involve the Cytochrome P450 3A4 (CYP3A4) enzyme pathway.

Co-administration with strong CYP3A4 inhibitors (such as Ketoconazole, Itraconazole, and Ritonavir) is documented to increase the systemic plasma exposure of Amlodipine. Conversely, co-administration with CYP3A4 inducers (e.g., Rifampin) may lead to a reduction in Amlodipine's plasma concentration.

---

Documented Interaction Constraints

Interacting Substance	Official Regulatory Outcome / Restriction
Simvastatin (a statin)	Amlodipine increases its systemic exposure; the regulatory maximum daily dose of Simvastatin must not exceed 20 mg when co-administered.
Anti-hypertensive Agents	Potential for additive blood pressure-lowering effects (pharmacodynamic potentiation) with other agents, including Beta-blockers and PDE5 Inhibitors.
Grapefruit/Grapefruit Juice	Classified as a CYP3A4 inhibitor that may increase Amlodipine exposure.
Hepatic Impairment	Patients with impaired hepatic function may experience a more pronounced increase in exposure when co-administered with CYP3A4 inhibitors.

These interactions necessitate adherence to specific co-administration guidelines, ensuring all relevant changes to drug exposure or effects are managed according to regulatory labeling.

How Vasalat Works

Vasalat (Amlodipine) functions exclusively as a selective inhibitor of the Ca^2+-dependent mechanisms that regulate arterial tone. Its action initiates a controlled physiological cascade, moving from the molecular level to systemic change.

---

Targeting Voltage-Dependent Calcium Channels

Vasalat exerts its primary biological effect by acting as an antagonist of the L-type voltage-dependent calcium channel (CaV 1.2), which is preferentially located on the smooth muscle cells of the peripheral arteries. By binding to this target, the drug prevents the necessary influx of extracellular calcium ions into the muscle cell, thereby blocking the fundamental trigger for contraction and initiating smooth muscle relaxation.

---

Reducing Systemic Vascular Resistance

The resulting widespread relaxation of arterial smooth muscle (vasodilation) directly modulates the crucial physiological domain of Systemic Vascular Resistance (SVR), also known as afterload. This mechanism results in a reduction of the total mechanical resistance (afterload), which physiologically results in a decrease in arterial pressure. The slow kinetics of the drug's interaction with its channel target ensure that this modulation of resistance is sustained and gradual, reflecting a gradual rate of change in vascular tone.

How to Use Vasalat

Administration of Vasalat (Amlodipine) follows standardized protocols that characterize its usage as a chronic, once-daily medication. The protocol focuses on the correct route, dosage limits, and timing adjustments, without addressing therapeutic outcomes or safety information.

---

Official Administration Guidelines

Feature	Standard Instruction
Route of Administration	Oral route (swallowed by mouth).
Frequency	Once daily dosing schedule.
Meal Timing	May be taken with or without food, as absorption is not altered.
Missed Dose Rule	If a dose is missed, it should be taken as soon as remembered on that day; doses must not be doubled.

---

Dosing Schedule and Adjustment

For adults, the usual initial dose is 5 mg once daily. The maximum recommended daily intake is 10 mg. To allow for the drug to reach stable levels in the body, dosage adjustments, if required, should generally proceed slowly over a minimum period of 7 to 14 days.

Specific dosage considerations apply to certain groups. Patients who are older or who have hepatic impairment may be started on a lower initial dose of 2.5 mg once daily, and any subsequent dose increases must be approached cautiously and slowly. For pediatric patients (ages 6–17) with hypertension, the starting dose is 2.5 mg once daily, with an upper limit of 5 mg once daily. Dosage adjustments are generally not required for individuals with renal impairment.

These instructions define the structured, time-dependent approach to introducing and maintaining the medicine, ensuring its usage remains strictly within established parameters.

Research evidence / Overview of studies for Vasalat

Research for Vasalat (Amlodipine) includes a large volume of studies, primarily Randomized Controlled Trials (RCTs) and meta-analyses. These studies monitored patient outcomes over both short-term periods (weeks) for immediate measurements and long-term periods (years) to track major cardiovascular events. Research mainly examined the measurement of changes in blood pressure, the tracking of episodes of chest discomfort, and the monitoring of long-term functional patterns.

Evidence for use in Hypertension (High Blood Pressure)

The research for using Vasalat in high blood pressure includes extensive long-term comparative studies and large-scale meta-analyses. Researchers explored the use of amlodipine-based regimens against other standard anti-hypertensive drugs over periods typically ranging from three to six years. These studies monitored adults with hypertension, including populations with other health risks like diabetes. Findings describe patterns observed in the studies where the occurrence of stroke and heart attack was tracked over several years, including comparisons with other anti-hypertensive regimens.

Evidence for use in Angina Pectoris

The research base for using Vasalat in conditions involving chest discomfort is derived from randomized, placebo-controlled trials. For Chronic Stable Angina, research focused on outcomes reflecting daily functioning or activity level, monitoring changes in Total Exercise Time and the frequency of angina attacks. For Vasospastic Angina, research relevant in trials assessing short-term or episodic symptom patterns was explored. Studies reported patterns related to measured symptom variability for both forms of the condition.

What is Still Uncertain About Vasalat (Research Gaps)

Official sources point out that long-term effects are not fully established when comparing Vasalat directly to a placebo over many years for major cardiovascular outcomes. Additionally, data for certain groups remain insufficient, particularly for long-term functional patterns in the pediatric population (under age 17). Follow-up durations were limited in the initial studies for this group. Research findings describe group patterns, not personal outcomes.

Key Studies & References

1. Amlodipine in the Treatment of Patients with Stable Angina Pectoris

Common questions about Vasalat (FAQ)

---

Q: Why is Vasalat usually taken at a certain time of day?

The official once-daily dosing is determined by the drug's extended presence in the body. According to regulatory documents, Vasalat has a prolonged terminal half-life, which typically ranges from 30 to 50 hours. This sustained action is intended to provide sustained therapeutic coverage over a full 24-hour period.

---

Q: How quickly does Vasalat start to work?

Vasalat has a gradual onset of action, meaning its full effect does not occur immediately. Official product information indicates that the concentration of the drug reaches its highest level in the blood typically between 6 and 12 hours after a single oral dose.

---

Q: Are there any specific foods I should avoid while taking Vasalat?

The only specific food interaction documented in official regulatory materials is with grapefruit or grapefruit juice. This is because consuming grapefruit can increase the amount of Vasalat in the blood. Otherwise, Vasalat may generally be taken with or without food, as its absorption is not altered.

---

Q: Is Vasalat suitable for older adults?

Regulatory documents state that normal dosage regimens are generally recommended for older patients. However, if a dosage adjustment is needed, any increase in the dosage must be approached cautiously and slowly.

---

Q: What does 'contraindication' mean in relation to Vasalat?

In the context of Vasalat, a contraindication refers to specific conditions or circumstances that officially preclude the use of the medicine. This includes known hypersensitivity to the drug or other severe health conditions like severe hypotension (low blood pressure).

---

Q: What is the general duration of effect for a dose of Vasalat?

Official information describes Vasalat as a long-acting agent with a terminal elimination half-life typically between 30 and 50 hours. This prolonged duration of action means that the drug maintains its therapeutic effectiveness for at least 24 hours.

---

Q: Does Vasalat require any special monitoring?

While routine monitoring specifics are not mandated for all users, official warnings indicate that clinical monitoring may be necessary in certain situations. This includes when Vasalat is used alongside strong CYP3A4 inhibitor medicines or for patients with severe hepatic (liver) impairment.

---

Q: What does the research say about Vasalat's effect on quality of life?

Official research overviews indicate that studies focused on outcomes related to functional capacity, such as monitoring daily activity level and exercise tolerance. This research helps describe the patterns observed regarding the potential effects on a patient's daily life.

---

Q: What does the term 'drug interaction' mean for someone taking Vasalat?

The term 'drug interaction' describes a situation where another medicine or substance modifies the effect of Vasalat in the body. This can result in changes to the drug's overall exposure or lead to an additive blood pressure-lowering effect when combined with certain other agents.

---

Q: What's the meaning of 'efficacy' when talking about Vasalat research?

In the context of clinical research, efficacy refers to the measured success of the drug in producing its intended benefits. For Vasalat, this includes the ability to reduce blood pressure and track improvements in functional patterns like exercise time.

---

Q: What is the expected experience after starting treatment with Vasalat?

The effect of Vasalat begins gradually, and it maintains its action over a full day. Official information notes that certain common side effects, such as mild headache and dizziness, are reported to be most common during the initial period of treatment.

---

Q: Is Vasalat the same as [Name of similar drug]?

Vasalat is formally classified as a dihydropyridine Calcium Channel Blocker (CCB). While there are other medicines in the CCB class, each one has a unique chemical structure and specific profile regarding its duration of action and elimination from the body.

---

Q: Does Vasalat interact with common pain relievers?

Official patient information indicates a need for awareness regarding the use of over-the-counter products that may affect blood pressure. This includes certain non-steroidal anti-inflammatory drugs (NSAIDs).

---

Q: How long can a person safely stay on Vasalat?

Official guidance indicates that for patients managing chronic conditions like high blood pressure, the drug will likely need to be taken long-term. The medicine is generally used long-term to maintain its documented benefits.

---

Q: Can Vasalat be used for other purposes besides its main uses?

Official regulatory indications define the use of Vasalat exclusively for the treatment of high blood pressure (hypertension) and specific forms of chest discomfort (angina).

---

Q: Why do official documents mention specific lab tests related to Vasalat?

Official patient information states that the drug may affect the results of certain lab tests, including blood work. Regulatory information indicates a need for patients to ensure all healthcare providers and lab personnel are aware they are taking the drug before any testing.

---

Q: Can Vasalat interact with herbal supplements?

Official interaction profiles list that certain substances which induce (speed up) the CYP3A4 enzyme pathway can affect the concentration of Vasalat. One example is the herbal supplement St. John's Wort (Hypericum perforatum).

---

Q: What should I do if a side effect of Vasalat seems unusual?

Official patient information provides guidance on when to seek assistance if side effects are bothersome, seem unusual, or persist. This information is provided to help patients understand official procedures for adverse event reporting.

---

Q: Is it okay to drink coffee while taking Vasalat?

Official guidance does not prohibit coffee consumption, but describes circumstances under which reducing intake of coffee and other caffeinated products may be considered if a patient experiences common side effects like flushing or a pounding heartbeat.

---

Q: What happens if I stop taking Vasalat suddenly?

Studies describe patterns where blood pressure generally returns to its previous baseline over approximately one week. A dangerous rebound effect is not reported as a characteristic pattern associated with stopping the drug.

---

Q: Does Vasalat affect the ability to drive or operate machinery?

Official product information states that Vasalat can have a minor to moderate influence on the ability to drive or use machines. This is especially true at the start of treatment or during dose increases, if a patient experiences side effects such as dizziness, headache, or fatigue.

---

Q: Are there any known interactions between Vasalat and alcohol?

Official patient information indicates that alcohol may have additive blood pressure-lowering effects when combined with Vasalat. This potentiation can result in increased dizziness, headache, or lightheadedness.

---

Q: Why is Vasalat sometimes given as a combination therapy?

Official indications state that Vasalat may be used in combination with other anti-hypertensive agents, such as diuretics or beta-blockers. This approach is generally used when a patient's blood pressure is not adequately managed by a single agent alone.

---

Q: Are there different strengths or forms of Vasalat available?

Official regulatory documents define the available strengths of the oral tablet for daily use. The strengths are typically defined as 2.5 mg, 5 mg, and 10 mg.

---

Q: Why does the packaging list so many potential side effects?

Regulatory authorities mandate that the official labeling must include all adverse reactions reported during clinical trials or post-marketing surveillance. These are grouped by frequency (e.g., Common, Rare) and system to provide comprehensive information.

---

Q: Are there any common interactions with over-the-counter cold medicines?

Official patient information indicates a need for awareness and caution regarding the use of over-the-counter cold remedies or cough drugs that may potentially raise blood pressure.

---

Q: How does Vasalat affect common blood tests?

Regulatory information indicates that the medicine may affect the results of certain lab tests, including blood work. Regulatory information indicates a need for patients to ensure all healthcare providers and lab personnel are aware they are taking the drug.

How to Store and Dispose of Vasalat?

The official labeled storage requirements for Vasalat define strict conditions to maintain the drug's stability and effectiveness.

Storage Domain	Official Regulatory Requirement
Temperature	Store undiluted vials under refrigeration at 2 C to 8 C (36 F to 46 F). Do not freeze.
Protection	Keep the undiluted vial in the original carton to protect from light and moisture.
In-Use Stability	The diluted solution is a single-dose vial and must be used within 8 hours when stored under refrigeration.

All medicines, including Vasalat, must be kept out of the sight and reach of children. Any unused portion of the diluted solution must be discarded. Disposal of expired or unused medicine should follow local waste disposal guidelines, often utilizing a drug take-back program or mixing the product with an undesirable substance before discarding in the household trash.